Open an account

Akebia Therapeutics

AKBA · NASDAQ

$0.6181−$0.062 (−9.12%)TodayMarket closed ·
Prev close $0.6801

About AKBA

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 194 full-time employees. The company went IPO on 2014-03-20. The firm's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The firm's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.

Employees
194
Headquarters
Cambridge, Massachusetts
Listed
Mar 20, 2014
Sector
Health Care
Industry
Biotechnology
Website
akebia.com

AKBA key statistics

Market cap
171.28M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
7.25M
Volume
9.98M
Open price
$0.68
High today
$0.7063
Low today
$0.6116
52 Week high
$3.20
52 Week low
$0.6659

Akebia Therapeutics (AKBA) at a glance

Akebia Therapeutics (AKBA) last traded at $0.6181, with a market cap of 171.28M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.6116 and $0.7063. The current price is 1.1% above the day's low and 12.5% below its high.

Volume so far is 9.98M shares, above the average of 7.25M shares a day.

Over the past year Akebia Therapeutics has ranged from $0.6659 to $3.20, and now sits -2% of the way up that range.

Akebia Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.03 per share against an estimate of -$0.0449.

The average analyst price target is $4.00, 546.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 8 analystsAvg $4.00
Low
$1.01
Now
$0.6181
High
$6.30

AKBA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 99.6% on average.

  1. Q3 FY24: reported -$0.10 per share against an estimate of -$0.0646
  2. Q4 FY24: reported -$0.10 per share against an estimate of -$0.0816
  3. Q1 FY25: reported $0.03 per share against an estimate of -$0.0459
  4. Q2 FY25: reported $0.00 per share against an estimate of -$0.0204
  5. Q3 FY25: reported $0.00 per share against an estimate of -$0.0179
  6. Q4 FY25: reported -$0.05 per share against an estimate of -$0.0255
  7. Q1 FY26: reported -$0.03 per share against an estimate of -$0.0286
  8. Q2 FY26: reported -$0.03 per share against an estimate of -$0.0449

AKBA news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

  • Uncovering Potential: Akebia Therapeutics's Earnings Preview

  • Where Akebia Therapeutics Stands With Analysts

  • Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views

  • Vandana Singh

    Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Similar companies

Companies in the same industry as Akebia Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.